{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:08:18Z","timestamp":1789247298450,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40121-026-01413-5","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:16:07Z","timestamp":1786716967000},"page":"2751-2771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria\u2014A Subgroup Analysis from the FORTRESS Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Klaus-Friedrich","family":"Bodmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mularoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Russelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Galfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Alessandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Mouloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavrina","family":"Avgeropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campogiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zacharowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Jarczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Iasonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele R.","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Myrianthefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Marangos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan T.","family":"Kielstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit M.","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Del Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Hatzilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios F.","family":"Assimakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G.","family":"Vossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio M.","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Borrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the FORTRESS study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"2","key":"1413_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cmi.2023.11.008","volume":"30","author":"M Paniagua-Garc\u00eda","year":"2024","unstructured":"Paniagua-Garc\u00eda M, Bravo-Ferrer JM, P\u00e9rez-Galera S, Kostyanev T, de Kraker MEA, Feifel J, et\u00a0al. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA). Clin Microbiol Infect. 2024;30(2):223\u201330.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"1413_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/cid\/ciad100","volume":"76","author":"M Falcone","year":"2023","unstructured":"Falcone M, Tiseo G, Carbonara S, Marino A, Di Caprio G, Carretta A, et\u00a0al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram-negative Bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis. 2023;76(12):2059\u201369.","journal-title":"Clin Infect Dis"},{"key":"1413_CR3","volume-title":"2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","author":"WHO Bacterial Priority Pathogens List","year":"2024","unstructured":"WHO Bacterial Priority Pathogens List. 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024."},{"issue":"10459","key":"1413_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et\u00a0al. Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. The Lancet. 2024;404(10459):1199\u2013226.","journal-title":"The Lancet"},{"key":"1413_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11030421","author":"C Aurilio","year":"2022","unstructured":"Aurilio C, Sansone P, Barbarisi M, Pota V, Giaccari LG, Coppolino F, et\u00a0al. Mechanisms of action of carbapenem resistance. Antibiotics (Basel). 2022. https:\/\/doi.org\/10.3390\/antibiotics11030421.","journal-title":"Antibiotics (Basel)"},{"issue":"7","key":"1413_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02000-20","volume":"65","author":"KM Kazmierczak","year":"2012","unstructured":"Kazmierczak KM, Karlowsky JA, de Jonge BLM, Stone GG, Sahm DF. Epidemiology of carbapenem resistance determinants identified in meropenem-nonsusceptible Enterobacterales collected as part of a global surveillance program, 2012 to 2017. Antimicrob Agents Chemother. 2021;65(7):e0200020.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1413_CR7","first-page":"249","volume":"33","author":"G Tiseo","year":"2025","unstructured":"Tiseo G, Stefani S, Fasano FR, Falcone M. The burden of infections caused by metallo-beta-lactamase-producing Enterobacterales in Italy: epidemiology, outcomes, and management. Infez Med. 2025;33(3):249\u201360.","journal-title":"Infez Med"},{"key":"1413_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101414","author":"M Papadimitriou-Olivgeris","year":"2022","unstructured":"Papadimitriou-Olivgeris M, Bartzavali C, Karachalias E, Spiliopoulou A, Tsiata E, Siakallis G, et\u00a0al. A seven-year microbiological and molecular study of bacteremias due to carbapenemase-producing Klebsiella pneumoniae: an interrupted time-series analysis of changes in the carbapenemase gene\u2019s distribution after introduction of ceftazidime\/avibactam. Antibiotics (Basel). 2022. https:\/\/doi.org\/10.3390\/antibiotics11101414.","journal-title":"Antibiotics (Basel)"},{"key":"1413_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2025.12.006","author":"CM Yu","year":"2025","unstructured":"Yu CM, Chiang TT, Tsai MH, Wang CH. Emergence of bla(NDM)-producing carbapenem-resistant Klebsiella pneumoniae replacing bla(KPC)-producing strains in a tertiary-care hospital after the introduction of ceftazidime\u2013avibactam: a concerning phenomenon requiring vigilance. J Microbiol Immunol Infect. 2025. https:\/\/doi.org\/10.1016\/j.jmii.2025.12.006.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"1413_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13756-025-01518-5","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Sholeh M, Yang L, Shakourzadeh MZ, Beig M, Azizian K. Global trends of ceftazidime\u2013avibactam resistance in gram-negative bacteria: systematic review and meta-analysis. Antimicrob Resist Infect Control. 2025;14(1):10.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"1413_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","volume":"30","author":"S Karakonstantis","year":"2024","unstructured":"Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(2):178\u201388.","journal-title":"Clin Microbiol Infect"},{"key":"1413_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13050963","author":"S Tedeschi","year":"2025","unstructured":"Tedeschi S, Giannitsioti E, Mayer C. Emerging concepts for the treatment of biofilm-associated bone and joint infections with IV fosfomycin: a literature review. Microorganisms. 2025. https:\/\/doi.org\/10.3390\/microorganisms13050963.","journal-title":"Microorganisms"},{"issue":"2","key":"1413_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321\u201347.","journal-title":"Clin Microbiol Rev"},{"key":"1413_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11121441","author":"B Kowalska-Krochmal","year":"2022","unstructured":"Kowalska-Krochmal B, M\u0105czy\u0144ska B, Rura\u0144ska-Smutnicka D, Secewicz A, Krochmal G, Bartelak M, et\u00a0al. Assessment of the susceptibility of clinical Gram-negative and Gram-positive bacterial strains to fosfomycin and significance of this antibiotic in infection treatment. Pathogens. 2022. https:\/\/doi.org\/10.3390\/pathogens11121441.","journal-title":"Pathogens"},{"issue":"12","key":"1413_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/antibiotics14121193","volume":"14","author":"ME Falagas","year":"2025","unstructured":"Falagas ME, Kontogiannis DS, Romanos LT, Ragias D, Agoranou ME, Kakoullis SA. Intravenous fosfomycin for Gram-negative and Gram-positive bacterial infections: a systematic review of the clinical evidence. Antibiotics. 2025;14(12):1193.","journal-title":"Antibiotics"},{"issue":"4","key":"1413_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","volume":"47","author":"KZ Vardakas","year":"2016","unstructured":"Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269\u201385.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1413_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2018.08.010","volume":"93","author":"RK Flamm","year":"2019","unstructured":"Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D. Activity of fosfomycin when tested against US contemporary bacterial isolates. Diagn Microbiol Infect Dis. 2019;93(2):143\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1413_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9080500","author":"RM Antonello","year":"2020","unstructured":"Antonello RM, Principe L, Maraolo AE, Viaggi V, Pol R, Fabbiani M, et\u00a0al. Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics. 2020. https:\/\/doi.org\/10.3390\/antibiotics9080500.","journal-title":"Antibiotics"},{"key":"1413_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00357-8","author":"A Russo","year":"2020","unstructured":"Russo A, Bassetti M, Bellelli V, Bianchi L, Marincola Cattaneo F, Mazzocchetti S, et\u00a0al. Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii: a prospective, observational study. Infect Dis Ther. 2020. https:\/\/doi.org\/10.1007\/s40121-020-00357-8.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1413_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106825","volume":"62","author":"A Russo","year":"2023","unstructured":"Russo A, Bruni A, Gull\u00ec S, Borrazzo C, Quirino A, Lionello R, et\u00a0al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62(1):106825.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1413_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107190","volume":"64","author":"A Russo","year":"2024","unstructured":"Russo A, Gull\u00ec SP, D\u2019Avino A, Borrazzo C, Carannante N, Dezza FC, et\u00a0al. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a multi-centre clinical experience. Int J Antimicrob Agents. 2024;64(1):107190.","journal-title":"Int J Antimicrob Agents"},{"key":"1413_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107365","author":"A Oliva","year":"2024","unstructured":"Oliva A, Curtolo A, Falletta A, Sacco F, Lancellotti F, Carnevalini M, et\u00a0al. Efficacy of fosfomycin-containing regimens in treating severe infections caused by KPC-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii in critically ill patients. Int J Antimicrob Agents. 2024. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107365.","journal-title":"Int J Antimicrob Agents"},{"key":"1413_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12020286","author":"SF Assimakopoulos","year":"2023","unstructured":"Assimakopoulos SF, Karamouzos V, Eleftheriotis G, Lagadinou M, Bartzavali C, Kolonitsiou F, et\u00a0al. Efficacy of fosfomycin-containing regimens for treatment of bacteremia due to pan-drug resistant Acinetobacter baumannii in critically ill patients: a case series study. Pathogens. 2023. https:\/\/doi.org\/10.3390\/pathogens12020286.","journal-title":"Pathogens"},{"key":"1413_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad435","author":"M Guastalegname","year":"2023","unstructured":"Guastalegname M, Trecarichi EM, Russo A. Intravenous fosfomycin: the underdog player in the treatment of carbapenem-resistant Acinetobacter baumannii infections. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad435.","journal-title":"Clin Infect Dis"},{"key":"1413_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01125-2","author":"KF Bodmann","year":"2025","unstructured":"Bodmann KF, Hagel S, Oliva A, Kluge S, Mularoni A, Galfo V, et\u00a0al. Real-world use, effectiveness, and safety of intravenous fosfomycin: the FORTRESS study. Infect Dis Ther. 2025. https:\/\/doi.org\/10.1007\/s40121-025-01125-2.","journal-title":"Infect Dis Ther"},{"key":"1413_CR26","unstructured":"Foundation for Statistical Computing (Vienna, Austria) R: a language and environment for statistical computing\u2014The R Project for Statistical Computing.\u00a0https:\/\/www.r-project.org\/."},{"key":"1413_CR27","unstructured":"Heinze G, Ploner M, Jiricka L, Steiner G. logistf: Firth\u2019s bias-reduced logistic regression. R package version 1.26.1. 2025. https:\/\/github.com\/georgheinze\/logistf."},{"issue":"2","key":"1413_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107247","volume":"64","author":"A Belati","year":"2024","unstructured":"Belati A, Diella L, Bavaro DF, De Santis L, Cotugno S, De Gennaro N, et\u00a0al. Intravenous fosfomycin as adjunctive therapy for Gram-negative bacteria bloodstream infections: a propensity score adjusted retrospective cohort study. Int J Antimicrob Agents. 2024;64(2):107247.","journal-title":"Int J Antimicrob Agents"},{"key":"1413_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12060971","author":"A Anastasia","year":"2023","unstructured":"Anastasia A, Bonura S, Rubino R, Giammanco GM, Miccich\u00e8 I, Di Pace MR, et\u00a0al. The use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in Italy. Antibiotics (Basel). 2023. https:\/\/doi.org\/10.3390\/antibiotics12060971.","journal-title":"Antibiotics (Basel)"},{"key":"1413_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010049","author":"A Marino","year":"2022","unstructured":"Marino A, Stracquadanio S, Campanella E, Munaf\u00f2 A, Gussio M, Ceccarelli M, et\u00a0al. Intravenous fosfomycin: a potential good partner for cefiderocol. Clinical experience and considerations. Antibiotics (Basel). 2022. https:\/\/doi.org\/10.3390\/antibiotics12010049.","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"1413_CR31","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","volume":"12","author":"DF Bavaro","year":"2023","unstructured":"Bavaro DF, Papagni R, Belati A, Diella L, De Luca A, Brindicci G, et\u00a0al. Cefiderocol versus colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted, monocentric cohort study. Infect Dis Ther. 2023;12(8):2147\u201363.","journal-title":"Monocentric Cohort Study Infect Dis Ther"},{"key":"1413_CR32","doi-asserted-by":"crossref","unstructured":"Oliva A, Volpicelli L, Di Bari S, Curtolo A, Borrazzo C, Cogliati Dezza F, et\u00a0al. Effect of ceftazidime\/avibactam plus fosfomycin combination on 30\u2005day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study. JAC Antimicrob Resist. 2022;4(6):dlac121.","DOI":"10.1093\/jacamr\/dlac121"},{"issue":"9","key":"1413_CR33","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","volume":"73","author":"M Tumbarello","year":"2021","unstructured":"Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et\u00a0al. Ceftazidime\u2013avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664\u201376.","journal-title":"Clin Infect Dis"},{"key":"1413_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.11.009","author":"M Rinaldi","year":"2025","unstructured":"Rinaldi M, Gatti M, Giannella M. Avoiding resistance development to newer drugs: open research lines. Clin Microbiol Infect. 2025. https:\/\/doi.org\/10.1016\/j.cmi.2025.11.009.","journal-title":"Clin Microbiol Infect"},{"key":"1413_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00479-7","author":"G Zheng","year":"2021","unstructured":"Zheng G, Zhang J, Wang B, Cai J, Wang L, Hou K, et\u00a0al. Ceftazidime\u2013avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime\u2013avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021. https:\/\/doi.org\/10.1007\/s40121-021-00479-7.","journal-title":"Infect Dis Ther"},{"key":"1413_CR36","doi-asserted-by":"crossref","unstructured":"Sader HS, Mendes RE, Carvalhaes CG, Kimbrough JH, Castanheira M. Changing epidemiology of carbapenemases among carbapenem-resistant Enterobacterales From United States hospitals and the activity of aztreonam-avibactam against contemporary Enterobacterales (2019\u20132021). Open Forum Infect Dis. 2023;10(2):ofad046.","DOI":"10.1093\/ofid\/ofad046"},{"issue":"5","key":"1413_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01406-22","volume":"67","author":"M Estabrook","year":"2018","unstructured":"Estabrook M, Muyldermans A, Sahm D, Pierard D, Stone G, Utt E. Epidemiology of resistance determinants identified in meropenem-nonsusceptible Enterobacterales collected as part of a global surveillance study, 2018 to 2019. Antimicrob Agents Chemother. 2023;67(5):e0140622.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1413_CR38","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1093\/jac\/dkaf161","volume":"80","author":"HS Sader","year":"2025","unstructured":"Sader HS, Kimbrough JH, Winkler ML, Castanheira M, Mendes RE. Aztreonam\/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019\u20132023). J Antimicrob Chemother. 2025;80(8):2070\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1413_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jac\/dkae367","volume":"80","author":"I Baltas","year":"2025","unstructured":"Baltas I, Patel T, Soares AL. Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol? J Antimicrob Chemother. 2025;80(1):59\u201367.","journal-title":"J Antimicrob Chemother"},{"key":"1413_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.050","author":"\u00c1 Sonnevend","year":"2020","unstructured":"Sonnevend \u00c1, Ghazawi A, Darwish D, Barathan G, Hashmey R, Ashraf T, et\u00a0al. In vitro efficacy of ceftazidime\u2013avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem resistant Enterobacterales from the Arabian Peninsula. Int J Infect Dis. 2020. https:\/\/doi.org\/10.1016\/j.ijid.2020.07.050.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"1413_CR41","first-page":"264","volume":"46","author":"MT Della Rocca","year":"2023","unstructured":"Della Rocca MT, Di Caprio G, Colucci F, Merola F, Panetta V, Cordua E, et\u00a0al. Fosfomycin-meropenem synergistic combination against NDM carbapenemase-producing Klebsiella pneumoniae strains. New Microbiol. 2023;46(3):264\u201370.","journal-title":"New Microbiol"},{"issue":"5","key":"1413_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/1120009X.2020.1745501","volume":"32","author":"B Erturk Sengel","year":"2020","unstructured":"Erturk Sengel B, Altinkanat Gelmez G, Soyletir G, Korten V. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and\/or NDM-producing Klebsiella pneumoniae. J Chemother. 2020;32(5):237\u201343.","journal-title":"J Chemother"},{"issue":"9","key":"1413_CR43","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/mdr.2018.0234","volume":"25","author":"D Ojdana","year":"2019","unstructured":"Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E. Activity of ceftazidime\u2013avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist. 2019;25(9):1357\u201364.","journal-title":"Microb Drug Resist"},{"issue":"6","key":"1413_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00107-24","volume":"12","author":"Y Wu","year":"2024","unstructured":"Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, et\u00a0al. Effect of ceftazidime\u2013avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr. 2024;12(6):e0010724.","journal-title":"Microbiol Spectr"},{"issue":"12","key":"1413_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/antibiotics14121247","volume":"14","author":"E Wohlfarth","year":"2025","unstructured":"Wohlfarth E, Dinh A, Vrioni G, \u017babicka D, Bernardo M, Tascini C, et\u00a0al. In vitro evaluation of fosfomycin combinations against metallo-\u03b2-lactamase-producing Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates. Antibiotics. 2025;14(12):1247.","journal-title":"Antibiotics"},{"issue":"6","key":"1413_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13855","volume":"17","author":"P Karnmueng","year":"2024","unstructured":"Karnmueng P, Montakantikul P, Paiboonvong T, Plongla R, Chatsuwan T, Chumnumwat S. Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48. Clin Transl Sci. 2024;17(6):e13855.","journal-title":"Clin Transl Sci"},{"issue":"11","key":"1413_CR47","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, et\u00a0al. Efficacy of ceftazidime\u2013avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales. Clin Infect Dis. 2021;72(11):1871\u20138.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1413_CR48","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/cid\/ciad725","volume":"78","author":"M Falcone","year":"2024","unstructured":"Falcone M, Giordano C, Leonildi A, Galfo V, Lepore A, Suardi LR, et\u00a0al. Clinical features and outcomes of infections caused by metallo-\u03b2-lactamase-producing Enterobacterales: a 3-year prospective study from an endemic area. Clin Infect Dis. 2024;78(5):1111\u20139.","journal-title":"Clin Infect Dis"},{"key":"1413_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14040401","author":"V Zerbato","year":"2025","unstructured":"Zerbato V, Sanson G, Fusaro L, Gerussi V, Sincovich S, Dellai F, et\u00a0al. Intravenous fosfomycin for difficult-to-treat infections: a real-life multicentric study in Italy. Antibiotics (Basel). 2025. https:\/\/doi.org\/10.3390\/antibiotics14040401.","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"1413_CR50","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s15010-019-01323-4","volume":"47","author":"C Putensen","year":"2019","unstructured":"Putensen C, Ellger B, Sakka SG, Weyland A, Schmidt K, Zoller M, et\u00a0al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019;47(5):827\u201336.","journal-title":"Infection"},{"key":"1413_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf020","author":"AP MacGowan","year":"2025","unstructured":"MacGowan AP, Griffin P, Attwood MLG, Daum AM, Avison MB, Noel AR. The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection. J Antimicrob Chemother. 2025. https:\/\/doi.org\/10.1093\/jac\/dkaf020.","journal-title":"J Antimicrob Chemother"},{"key":"1413_CR52","doi-asserted-by":"crossref","unstructured":"Farooq A, Martens M, Attwood MLG, Nordmann P, MacGowan A, Wicha SG. Meropenem and fosfomycin against K. pneumoniae: towards a combination breakpoint using a pharmacometric approach. Clin Microbiol Infect. 2026.","DOI":"10.1016\/j.cmi.2026.02.024"},{"issue":"12","key":"1413_CR53","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/cid\/ciz181","volume":"69","author":"KS Kaye","year":"2019","unstructured":"Kaye KS, Rice LB, Dane A, Stus V, Sagan O, Fedosiuk E, et\u00a0al. Fosfomycin for injection (ZTI-01) vs piperacillin-tazobactam (PIP-TAZ) for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP): ZEUS, a phase 2\/3 randomized trial. Clin Infect Dis. 2019;69(12):2045\u201356.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1413_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37277","volume":"5","author":"J Sojo-Dorado","year":"2022","unstructured":"Sojo-Dorado J, L\u00f3pez-Hern\u00e1ndez I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hern\u00e1ndez-Torres A, et\u00a0al. Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2137277.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1413_CR55","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cmi.2025.01.007","volume":"31","author":"E Moreno-Mellado","year":"2025","unstructured":"Moreno-Mellado E, Aslan AT, Akova M, Le\u00f3n E, Merchante N, Vinuesa D, et\u00a0al. Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project. Clin Microbiol Infect. 2025;31(5):839\u201346.","journal-title":"Clin Microbiol Infect"},{"key":"1413_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae197","author":"M Falcone","year":"2024","unstructured":"Falcone M, Tiseo G. Fosfomycin as a potential therapeutic option in nonsevere infections caused by metallo-\u03b2-lactamase-producing Enterobacterales: need for evidence. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae197.","journal-title":"Clin Infect Dis"},{"key":"1413_CR57","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jgar.2024.12.013","volume":"41","author":"J Rodr\u00edguez-G\u00f3mez","year":"2025","unstructured":"Rodr\u00edguez-G\u00f3mez J, Gracia-Ahufinger II, Carmona-Flores R, Guzm\u00e1n-Puche J, Le\u00f3n R, P\u00e9rez-Nadales E, et\u00a0al. Efficacy of high doses of intravenous fosfomycin for treatment of urinary tract infection caused by KPC carbapenemase-producing Klebsiella pneumoniae: an observational study. J Glob Antimicrob Resist. 2025;41:138\u201343.","journal-title":"J Glob Antimicrob Resist"},{"key":"1413_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jgar.2023.03.010","volume":"33","author":"G Zhanel","year":"2023","unstructured":"Zhanel G, Baxter M, Wong M, Mirzanejad Y, Lee A, Dhami R, et\u00a0al. Real-life experience with IV fosfomycin in Canada: results from the Canadian Leadership on Antimicrobial Real-Life Usage (CLEAR) registry. J Glob Antimicrob Resist. 2023;33:171\u20136.","journal-title":"J Glob Antimicrob Resist"},{"key":"1413_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124386","author":"F Luciano","year":"2025","unstructured":"Luciano F, Bertolino L, Patauner F, Boccia F, Gallo R, Sommese P, et\u00a0al. Efficacy and safety of fosfomycin disodium in patients with bacterial infections: a single-center, real-life clinical study. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14124386.","journal-title":"J Clin Med"},{"issue":"1","key":"1413_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","volume":"37","author":"A Florent","year":"2011","unstructured":"Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37(1):82\u20133.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"1413_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-051208","volume":"11","author":"S Grillo","year":"2021","unstructured":"Grillo S, Cuervo G, Carratala J, San-Juan R, Aguado JM, Morata L, et\u00a0al. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: study protocol for the SAFO trial. BMJ Open. 2021;11(8):e051208.","journal-title":"BMJ Open"},{"key":"1413_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.844122","volume":"13","author":"C Scavone","year":"2022","unstructured":"Scavone C, Mascolo A, Bernardi FF, Aiezza ML, Saturnino P, Morra G, et\u00a0al. Hypernatremia during intravenous treatment with fosfomycin: a retrospective medical record review study and an analysis of spontaneous reports in the Eudravigilance database. Front Pharmacol. 2022;13:844122.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1413_CR63","doi-asserted-by":"publisher","first-page":"e01682","DOI":"10.1128\/AAC.01682-18","volume":"62","author":"GL Drusano","year":"2018","unstructured":"Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D, Maynard M, et\u00a0al. The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model. Antimicrob Agents Chemother. 2018;62(12):e01682\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1413_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2197","author":"E Garcia","year":"2021","unstructured":"Garcia E, Diep JK, Sharma R, Hanafin PO, Abboud CS, Kaye KS, et\u00a0al. Evaluation strategies for triple-drug combinations against carbapenemase-producing Klebsiella pneumoniae in an in vitro hollow-fiber infection model. Clin Pharmacol Ther. 2021. https:\/\/doi.org\/10.1002\/cpt.2197.","journal-title":"Clin Pharmacol Ther"},{"key":"1413_CR65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00293-21","author":"CA Darlow","year":"2021","unstructured":"Darlow CA, Docobo-Perez F, Farrington N, Johnson A, McEntee L, Unsworth J, et\u00a0al. Amikacin combined with fosfomycin for treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/AAC.00293-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1413_CR66","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1128\/AAC.00752-15","volume":"59","author":"F Docobo-P\u00e9rez","year":"2015","unstructured":"Docobo-P\u00e9rez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Mart\u00edn V, et\u00a0al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(9):5602\u201310.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01413-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:41:28Z","timestamp":1789245688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01413-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01413-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964 (and its amendments) and was approved by all ethics committees or other authorities according to national\/local requirements. Written informed consent was obtained from each patient or the patient\u2019s legally acceptable representative before any study-specific activity was performed. Full details of the ethical approval have been previously reported [\n                      \n                      ].","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following authors declare potential conflicts of interest unrelated to the submitted work: Klaus-Friedrich Bodmann has received honoraria for lectures from Abbott, Accelerate, Correvio, InfectoPharm, Pfizer, Weber & Weber, and Shionogi.\u00a0Loredana Sarmati received travel grants from Gilead, Merck, Pfizer, and Advanz. She also received honoraria for lectures from Merck, Gilead, Abbvie, Angelini, AstraZeneca, and GSK. Laura Campogiani received a research grant from Gilead and honoraria for lectures from Menarini, MICOM, and Nadirex. She also reports support for attending meetings from Menarini, Shionogi, and Pfizer. Ivan Gentile reports departmental research grants from Advanz Pharma, as well as consulting fees and honoraria for lectures from MSD, Pfizer, GSK, Basilea, InfectoPharm, Angelini, Shionogi, Advanz Pharma, Abbott, and AstraZeneca. He also participated in advisory boards for MSD, Pfizer, GSK, Basilea, InfectoPharm, Angelini, Shionogi, Advanz Pharma, Abbott, and AstraZeneca. Kai Zacharowski received speaker fees from CSL Behring, Masimo, Pharmacosmos, Boston Scientific, Salus, iSEP, Edwards, Hemosonics, Baxter Deutschland GmbH, and GE Healthcare. Stefan Kluge received research support from Biotest, CytoSorbents, Daiichi Sankyo, and Fresenius Medical Care; consultant fees from ADVITOS, Gilead, and Pfizer; and lecture fees from ADVITOS, bioM\u00e9rieux GmbH, CSL Behring, Gilead, MSD, Pfizer, and Shionogi. Stefan Hagel has received honoraria from Pfizer, MSD, InfectoPharm, Philips, Advanz Pharma, Beckman Coulter, Shionogi, Thermo Fisher, and Tillotts. He also participated in advisory boards for Advanz Pharma, Shionogi, and Pfizer. Daniele Roberto Giacobbe reports investigator-initiated grants from Pfizer, Shionogi, Advanz Pharma, bioM\u00e9rieux, Tillotts Pharma, and Menarini; travel support from Pfizer, bioM\u00e9rieux, and Menarini; and speaker\/advisor fees from Menarini, Shionogi, Pfizer, Advanz Pharma, bioM\u00e9rieux, and MSD. Markos Marangos reports consulting fees from MSD, Menarini, and GSK; honoraria for lectures and presentations from MSD, Menarini, Gilead, Norma, GSK, and Pfizer; and support for attending meetings from MSD, GSK, Gilead, and Pfizer. Stelios F. Assimakopoulos has received honoraria from Pfizer, Gilead, GSK, MSD, Menarini, Angelini, InfectoPharm, Norma, Uni-pharma, and Elpen; participated in advisory boards for Pfizer, MSD, GSK, Gilead, and Menarini; and received research support or grants from Pfizer, Gilead, and Elpen. Evangelos J. Giamarellos-Bourboulis reports honoraria from Abbott Products Operations, bioM\u00e9rieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi, and Xbiotech Inc.; independent educational grants from Abbott Products Operations, bioM\u00e9rieux Inc., MSD, UCB, and Swedish Orphan Biovitrum AB; and funding from the Horizon 2020 European Grants ImmunoSep and RISCinCOVID, and the Horizon Health grants EPIC-CROWN-2, POINT, and Homi-Lung (granted to the Hellenic Institute for the Study of Sepsis). Mathias W. Pletz received grants from Pfizer, consulting fees from Sanofi and Pfizer, and honoraria for lectures and presentations from Pfizer, MSD, Sanofi, Janssen, GSK, AstraZeneca, Shionogi, InfectoPharm, bioM\u00e9rieux, and Moderna. He also reports support for attending meetings from Pfizer, MSD, Sanofi, bioM\u00e9rieux, and Shionogi, and participated in advisory boards for bioM\u00e9rieux, Sanofi, Pfizer, GSK, AstraZeneca, Shionogi, InfectoPharm, Tillotts, and Moderna. Alessandra Oliva has received speaker\u2019s honoraria for educational meetings from Shionogi; honoraria for participation in a scientific board from Mundipharma, Advanz-Pharma, and Pfizer; and speaker\u2019s honoraria from InfectoPharm. Matthias G. Vossen received consulting fees, speaker honoraria, and payment for expert testimony from Astro Pharma. Alessandra Mularoni, Giovanna Russelli, Valentina Galfo, Giusy Tiseo, Francesco Alessandri, Giancarlo Ceccarelli, Eleni Mouloudi, Stavrina Avgeropoulou, Dominik Jarczak, Christina Iasonidou, Alessandro Capone, Alessandra Bandera, Annalisa Saracino, Pavlos Myrianthefs, Michael Zoller, Jan T. Kielstein, Carlo Tascini, Antonio Cascio, Abhijit M. Bal, Francesca Ferretti, Valerio Del Bono, Despina Hatzilia, Marco Falcone, George Dimopoulos, Matteo Bassetti, and Claudio\u00a0M.\u00a0Mastroianni have nothing to declare. Thomas Borrmann and Christian Mayer are employees of InfectoPharm, Heppenheim, Germany.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}